

## **International Journal of ChemTech Research**

CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555

Vol.12 No.1, pp 26-48, 2019

# **Marine Sponges: Repositories of Bioactive compounds with Medicinal applications**

**Sasireka Rajendran<sup>1</sup>**

**<sup>1</sup>Department of Biotechnology, Mepco Schlenk Engineering College, Sivakasi, India**

**Abstract :** Marine Sponges and its associated symbiotic organisms are considered as the depositories of bioactive compounds and secondary metabolites naturally. Compounds in specific can be used for different applications as a drug candidate. It is believed that sponges have the potential to cure various diseases such as malaria, cancer and other viral infections. Eventhough the mechanism of action is still unclear for few cases, compounds in crude extracts interferes with the pathogenesis of different diseases. Based on the preliminary screening results of *in vitro* and *in vivo* studies, researchers are trying to formulate medicinal products out of this crude extract and to commercialize in the market. Chemical compounds of few sponges have varying carbon skeletons which have the ability to fight against different pathogens and may provide immunity to individuals affected by various diseases.

**Key Words :** Sponges, Bioactive Compounds, Secondary Metabolites, Malaria, Cancer.

### **Introduction:**

Marine environment is a reservoir of natural bioactive products which is of having pharmaceutical importance. Marine organisms normally produce naturalbioactive compounds for protection, communication and reproduction against predation, infection and competition. These natural products serve as a source for invention of new molecules and are considered as the most important drug lead in different fields.

Marine sponges are sessile animals that look like plants which attached themselves to a rock, shell or seafloor when they are young and live there for the rest of their lives.Sponges belong to the phylum Porifera, are oldest and simplest of multicellular animals with bodies full of pores which show relatively little differentiation and tissue coordination<sup>1</sup>. 8000 species were identified which were found throughout tropical, temperate and polar regions. Sponges are considered as an important component of pharmaceutical bioactive compounds among other marine sources. Discovery of Marine based natural products began in 1950s by the identification of nucleosides products spongorthymidine and spongouridine in the marine sponge *Cryptotheca crypta*<sup>2,3</sup>.Marine sponges and its associated microbes, seaweeds, soft and hard corals, gorgonians, cnidarians, etc is considered as factories for several pharmaceutical drugs. Nucleosides, Alkaloids, Steroids, Peptides, Terpenoids, Isoprenoids, Prostaglandins, Quinones, Brominated Compounds and Toxins are the major products of marine sponges which are of having prime importance.

**Sasireka Rajendran /International Journal of ChemTech Research, 2019,12(1): 26-48.**

**DOI= <http://dx.doi.org/10.20902/IJCTR.2019.120103>**

Nowadays, bioactive compounds from marine sources are of great importance. Bioactive substances from marine sponges or other associated microbes posses antibacterial, antiviral, antifungal, antileishmanial activity, antihelmintic activity, anti-inflammatory, antimarial, antifouling, antibiotics, analgesic, antiallergic activity, antithrombotic activity, antihypertensive, immunomodulatory, hepatoprotective activity and neurosuppressive function.

Marine sponges have the potential to provide future drugs against important diseases such as malaria, cancer and other viral diseases<sup>4</sup>. Sponges are classified into three main classes such as Calcarea, Demospongiae and Hexactinellida. Among these, it was found that Demospongiae is the major source of bioactive compounds. In addition to bioactive substances, sponges produce secondary metabolites which help to defend themselves against foreign prokaryotic and eukaryotic organisms.

Microbes such as bacteria, fungi and microalgae are also associated with marine sponges with beneficiary impact. Most common symbiont associated with marine sponges is bacteria and fungi whereas bacterial species outnumber fungal species. Cyanobacteria, Bacteriodetes, Actinobacteria, Chloroflexi, Proteobacteria, Nitrospira, Poribacteria, Verrucomicrobia Planctomycetes, Archaea and Acidobacteria are the major bacterial species that are associated with marine sponges. Discovery of pharmaceutically active substances from symbionts associated with marine sponges is also of greater interest. Bacterial phylum actinobacteria and fungal division ascomycota are the prime producers of bioactive compounds among other species.

In this review, pharmacologically active substances as potential drug candidates from marine sponges were focused.

#### **Antimicrobial activity (Antibacterial and Antifungal):**

Antibiotic resistant bacterium like *Staphylococcus aureus* creates a considerable problem and is involved in causing major infections. Presently many antibiotics became resistant by many strains which led to the discovery of newer class of antibiotics. Crude extracts obtained from marine sponges exhibit varying antibacterial activity for marine and terrestrial bacteria<sup>5,6,7,8,9</sup>. Selected crude extracts obtained from sponges have antibacterial activity against Gram positive and Gram negative species. Nearly 800 potent antibiotic substances were identified from marine sponges<sup>10</sup>. Eventhough antibiotic substances were identified, no antibacterial product was reported yet in the discovered marine natural product but many of them are under investigation in current research.

Fungal infection is predominant in the case of patients suffering from AIDS, immune depressants, hematological malignancies and transplant recipients which led to the development of novel compounds with antifungal activity<sup>11,12</sup>. It remains a major cause of death in patients who are treated for malignant disease<sup>13</sup>. Immunocompromised persons are severely infected by *Candida*, *Aspergillus*, *Cryptococcus* and other opportunistic fungi. In order to provide solution to these fungal associated problems new anti-fungal agents has to be discovered. Several species of marine sponges were screened for antimicrobial activity and are listed in the table 1.

**Table 1: Selected marine species with antimicrobial activity.**

Sponge	Compound/class	Function / Target Species	Reference
<i>Aplysia aerophoba</i> , <i>Verongia thiona</i>	Aerothionin	Antibiotic, <i>M. tuberculosis</i>	14
<i>Agelas oroides</i>	4,5-dibromopyrrole-2-carboxylic acid (Carboxylic acid)	Alters cellular calcium signals	15
<i>Phakellia flagellate</i>	Dibromophakellin (Alkaloids)	Antibacterial	16
<i>Halichondria mooriei</i>	Halistanol (Sterol)	<i>Streptococcus</i> sp	17

<i>Plakina</i> sp.	Plakinamine A (Steroidal alkaloid)	<i>Staphylococcus aureus</i> , <i>Candida albicans</i> .	18
<i>Plakina</i> sp.	Plakinamine B (Steroidal alkaloid)	<i>Staphylococcus aureus</i> , <i>Candida albicans</i> .	18
<i>Dysidea</i> , <i>Euryspongia</i> and <i>Siphonodictyon</i> species.	Furanoid (sesquiterpenoids)	Anti-bacterial	19
<i>Aplysina caissara</i>	Bromotyrosine compounds such as Fistyralin-3 and 11-hydroxyaerothionin	Antibiotic activity <i>E. coli</i> , <i>P. aeruginosa</i> and <i>S. aureus</i>	20
<i>Cliona varians</i>	Lectins	Cytotoxic activity Gram positive bacteria, such as <i>Bacillus subtilis</i> , <i>Staphylococcus aureus</i> and agglutinated <i>Leishmania chagasi</i> , promastigotes	21
<i>Ircinia</i> sp.	Unknown	Antibiotic, analgesic and anti-inflammatory properties	20
<i>Sigmadocia pumila</i>	Unknown	Gram positive bacterial strains included <i>Bacillus thuringiensis</i> MTCC 4714, <i>Enterococci fecalis</i> MTCC 439, <i>Listeriamonocytogenes</i> MTCC 1143, <i>Staphylococcus aureus</i> , MTCC 737 and <i>Proteus vulgaris</i> MTCC 426.  Gram negative strains such as the <i>E. coli</i> MTCC 443, <i>Klebsiellapneumonia</i> MTCC 109, <i>Pseudomonas putida</i> MTCC 1688 and <i>Serratia liquefaciens</i> MTCC 3039  Antifungal <i>Trichoderma viride</i> MTCC 2047, <i>Fuzarium</i> spMTCC 284, <i>Aspergillus niger</i> MTCC 1344, <i>Candida albicans</i> MTCC 183, <i>Penicillium chrysogenum</i> MTCC 5108 and <i>Aspergillus flavis</i> MTCC 873	20
<i>Aplysina cavernicola</i>	Aeroplysinin and aerthionin and other dibromo and dichlorotyrosine derivatives	Antibiotic <i>Bacillus subtilis</i> and <i>Proteus vulgaris</i>	22
<i>Stylotella aurantium</i>	Unknown	<i>Bacillus cereus</i> , <i>Escherichia coli</i> , <i>Salmonella typhi</i> and <i>Staphylococcus aureus</i> .	23
<i>Haliclona molitba</i>	Unknown	<i>Bacillus cereus</i> , <i>Escherichia coli</i> , <i>Salmonella typhi</i> , and <i>Staphylococcus aureus</i> .	23

<i>Luffariella variabilis</i>	Manoalide	<i>Staphylococcus aureus</i> and <i>Bacillus subtilis</i>	24
<i>Zygomycale</i> sp	Unknown	<i>Bacillus subtilis</i> , <i>Proteus vulgaris</i> , <i>Escherichia coli</i>	24
<i>Cinachyrella</i> sp., <i>Haliclona</i> sp. and <i>Petromica citrina</i>	Unknown	Antibacterial activity coagulase-negative <i>Staphylococci</i> (CNS) strains (responsible for causing bovine mastitis), including strains resistant to conventional antibiotics	24
<i>Discodermia kiiensis/Lithistida</i>	Discodermins B, C and D (Cyclic peptide)	Antibacterial <i>B. subtilis</i>	25
<i>Arenosclera brasiliensis</i>	Arenosclerins A-C (Alkyl pepridine alkaloid)	Antibacterial <i>S. aureus</i> , <i>P. aeruginosa</i> ,	10
<i>Arenosclera brasiliensis</i>	Haliclona cyclamine E (Alkylpiperidine alkaloids)	<i>S. aureus</i> , <i>P. aeruginosa</i>	10
<i>Cliona varians</i>	CvL (Lectin)	Antibacterial <i>S. aureus</i> , <i>B. subtilis</i>	21
<i>Axinella</i> sp./ <i>Halichondrida</i>	Axinellamines B-D (Imidazo-azolo-imidazole alkaloid)	Antibacterial <i>H. Pylori</i> , <i>M. Luteus</i>	26
<i>Caminus sphaeroconia</i>	Camino sides A-D (Glycolipids)	Antibacterial <i>E. coli</i> , <i>S. aureus</i>	27
<i>Acanthostrongylophora</i> sp.	6-hydroxymanzamine E (Alkaloid)	Antibacterial <i>M. tuberculosis</i>	28
<i>Cribrochalina</i> sp.	Cribrostatin 3 (Alkaloid)	Antibacterial <i>N.gonorrhoeae</i> (antibiotic resistant strain)	29
<i>Cribrochalina</i> sp.	Cribrostatin 6 (Alkaloid)	Antibacterial <i>S. pneumoniae</i> (antibioticresistant strain)	29
<i>Cacospongia</i> sp.	Isojaspic acid, cacospongin D and jaspquinol Meroditerpenes	Antibacterial <i>S. epidermidis</i>	30
<i>Aaaptos aaptos</i>	Isoaaptamine (Alkaloid)	Antibacterial <i>S. aureus</i>	31
<i>Fasciospongia</i> sp	(–)-Microcionin-1 (Terpenoid)	Antibacterial <i>M. Luteus</i>	32

<i>Haliclona exigua</i>	Unknown	Antifungal <i>Candida albicans, Cryptococcus neoformans, Aspergillus fumigatus, Candida parapsilosis.</i>	20
<i>Topsentia</i> sp./ <i>Halichondrida</i>	Topsentiasterol sulfates A-E (Sulfated sterol)	Antibacterial/antifungal (D and E)	33
<i>Acanthodendrilla</i> sp./ <i>Dendroceratida</i>	Acanthosterol I and J (Sulfated sterol)	Antifungal	34
<i>Oceanapia phillipensis/ Haplosclerida</i>	Oceanapiside (Bisaminohydroxylipid Glycoside)	Antifungal	35
<i>Hyrtios erecta/ Dictyoceratida</i>	Spongistatin (Polyether macrolide Lactone)	Antifungal	29
<i>Leucascandra caveolata/ Calcarea</i>	Leucascandrolide A (Oxazole-containing polyether macrolide)	Antifungal	36
<i>Lotrochota purpurea</i>	Halogenated alkaloids named purpuroines A-J	Inhibitory activity against diseases related to fungi and bacteria	37
<i>Haliclona</i> sp.	Novel cyclic bis-1,3-dialkylpyridiniums and cyclostellettamines	Moderate cytotoxic and antibacterial activities against A549 cell-line and Gram-positive strains	38
<i>Agelas mauritiana</i>	Alkaloids, (-)-8'-oxo-agelasine D, ageloxime B, (+)-2-oxo-agela-sidine C, 4-bromo-N-(butoxymethyl)-1H-pyrrole-2-carboxamide and (-)-ageloxime D	Antifungal activity <i>Cryptococcus neoformans</i> , antibacterial activity against <i>Staphylococcus aureus</i> and methicillin-resistant <i>S. aureus</i> <i>in vitro</i>	39

### Antitumour Compounds:

Numerous sponge derived compounds are inhibitors of Protein Kinase C. High levels of PKC enzyme are involved in the pathogenesis of arthritis and psoriasis (owing to the regulation of phospholipase A2 activity), and in tumor development. PKC is considered as the receptor protein of tumour promoting phorbol esters while PKC inhibitors prevent binding of carcinosarcoma cells to the endothelium. Receptors glycosylation especially fucose containing residues play an important role in the binding of carcinosarcoma cells and leukocytes to the receptors present in the endothelium.

Fucosyltransferase inhibitors, like octa and nonaprenylhydroquinone sulfates which were isolated from a *Sarcotragus* sp, could be used as a promising candidate to control inflammatory processes such as arthritis or for combating tumor growth. Numerous anti-tumour compounds with different mode of action are identified and are listed in the table 2. Compounds of which can be classified into three classes. Non Specific Inhibitors, Specific Inhibitors and Inhibitors of cancer cells of certain type of Cancer.

Compounds considered as non specific inhibitors are valuable for treating cancers but the major drawback is that it also affects healthy cells. Considering this it has limited application with specific characteristics. The cytoskeleton is an important target for cancer therapy, since microtubules and microfilaments are directly involved in cellular organization during cell division. One such example is adociasulfates (triterpenoid hydroquinones) from a *Haticlona* sp. were the first discovered inhibitors of the kinesin motor protein. The compound selectively inhibits the protein by binding to the microtubule binding site, “locking up” the proteins motor function, and thereby blocking cell division. In addition to this lot of potent microtubule interfering compounds have been discovered. Specific Inhibitors are specifically active against

tumour. Compounds for inhibitors of cancer cells of certain type of Cancer have been isolated but the mechanism of action is unclear.

**Table 2: Compounds which exhibit high antitumour activity.**

Sponge	Compound	Function	Reference
<i>Hyrtios</i> sp	Heteronemin (marine sesterterpene)	Affecting the cellular processes including apoptosis, cell cycle, MAPKs pathway(mitogen-activated protein kinases) and the nuclear factor kappa B (NF-kappaB) signaling cascade	40
<i>oceanapia sagittaria</i>	Kuanoniamines A and C (pyridoacrydine alkaloids)	A potent inhibitor of DNA synthesis and it was also found to cause an extensive reduction of the MCF-7 cells in G-2phase	41
<i>Thorectandra</i>	Thorectandrols	Anti Proliferative activity	42
<i>Aaptos aaptos/ Hadromerida</i>	Isoaaptamine (Benzonaphthyridine alkaloid)	Protein kinase C inhibitor	43
<i>Hymeniacidonialdis/ Halichondrida</i>	Debromohymenialdisine (Pyrrole-guanidine alkaloid)	Protein kinase C inhibitor	44
<i>Sarcotragus</i> sp./ <i>Dictyoceratida</i> <i>Haliclona</i> (aka <i>Adocia</i> ) sp./ <i>Haplosclerida</i>	Adociasulfates (Triterpenoid hydroquinones)	A1, 3-fucosyltransferase inhibitor Kinesin motor protein inhibitors	45
<i>Discodermia dissolute/ Lithistida</i>	Discodermolide (Linear tetraene lactone)	Stabilization of microtubules	46
<i>Mycdle hentschett/ Poecilosclerida</i>	Peloruside A (Macrocyclic lactone)	Stabilization of microtubules	47
<i>Plakinastrella</i> sp./ <i>Homosclerophorida</i>	Elenic acid (Alkylphenol)	Topoisomerase II inhibitor	47
<i>Leucetta cf. chagosensis</i>	Naamine D (Imidazole alkaloid)	Nitric oxide synthetase inhibitor	48
<i>Agelas mauritianus</i> / <i>Agelasida</i>	Agelasphin (KRN7000) ( $\alpha$ -Galactosylceramide)	NKT cell activator	49
<i>Crambe crambe/ Poecilosclerida</i>	Crambescidins 1-4 (Pentacyclic guanidine derivative)	Ca <sup>2+</sup> /channel blocker	50
<i>Latrunculia brevis/Poecilosclerida; Prianos</i> sp./ <i>Haplosclerida</i>	Discorhabdin D (Fused pyrrolophenanthroline alkaloid)	Unknown	51
<i>Aplysilla glacialis/ Dendroceratida</i>	Glaciasterols A and B 9, 11-Secosterol	Unknown	52
<i>Lobophytum duru</i>	Durumolides A-C (Terpenoid)	Inducible NOS and COX-2 inhibition	53
<i>Plakortis angulospiculatus</i>	Plakortide P (Polyketide)	TXB2 inhibition	54
<i>Hyrtios erectus</i>	24-methoxypetrosaspongia C (Sesterterpenes)	Unknown	55
<i>Calcareous sponge</i>	BRS1 (Diamino-dihydroxy polyunsaturated lipid)	Protein kinase C inhibitor	56

<i>Cacospongia mycofljiensis/ Dictyoceratida</i>	Laulimalide (Macrocyclic lactone)	Stabilization of microtubules	57
<i>Aulettia</i> sp./Halichondrida	Hemasterlin (Unusual tripeptide)	Stabilization of microtubules	58
<i>Corallistidae</i> sp./Lithistida	Dictyostatin (Macrocyclic lactone)	Stabilization of microtubules	59
<i>Halichondria okadai/</i> Halichondrida	Halichondrin B (Polyether macrolide)	Tubulin polymerisation inhibitor	60, 61
<i>Macrocyclic lactan/</i> lactone	Arenastatin A	Dysidea arenaria/ Dendroceratida	62
<i>Latrunculia magnified/</i> Poecilosclerida	Latrunculin A (Thiazole macrolide)	Actin-depolymerisation	63, 64
<i>Theonella swinhoei/</i> Lithistida	Swinholide A (Macrocyclic lactone)	Actin-depolymerization	65
<i>Mycale</i> sp./Poecilosclerida	Mycalolide B (Oxazole macrolide)	Actin-depolymerization	66, 67
<i>Xestospongia cf</i> <i>carbonaria/</i> Haplosclerida	Neoamphimedine (Pyridoacridine alkaloid)	Topoisomerase II inhibitor	68
<i>Spongia</i> sp./Dictyoceratida	Agosterol A (Sterol)	Reverses drug resistance of cancer cells	69
<i>Haliclona</i> sp./Haplosclerida	Salicylihalamide A (Salicylate macrolide)	v-ATPase inhibitor	70
<i>Chondropsis</i> sp./Poecilosclerida	Chondropsin A and B (Macrolide lactam)	v-ATPase inhibitor	71, 72
<i>Cinachyrella</i> sp./Spirophorida	6-Hydroximino-4-en-3-one Steroids (Oximated steroid)	Aromatase inhibitor	73
<i>Haliclona nigra/Haplosclerida</i>	Haligramides A and B (Cyclic peptide)	Unknown	74
<i>Latrunculia brevis/Poecilosclerida;</i> <i>Prianos</i> sp./Haplosclerida	Discorhabdin D (Fused pyrrolophenanthroline alkaloid)	Unknown	75
<i>Callyspongia truncata/Haplosclerida</i>	Callystatin A (Polyketide)	Unknown	76
<i>Tedania ignis/Poecilosclerida</i>	Tedanolide (Macrocyclic lactone)	Unknown	77
<i>Aplysilla glacialis/Dendroceratida</i>	Glaciasterols A and B 9, 11-Secosterol	Unknown	52
<i>Axinella carter!/Halichondrida</i>	Axinellins A and B (Cyclic peptide)	Unknown	78
<i>Dysidea incrassans/Dendroceratida</i>	Incrustasterols A and B (Sterol)	Unknown	79

**Anticancer compounds:****Table 3: Compounds with high anticancer activity.**

Sponge	Compound	Function	Reference
Discodermolide	Modified halichondrin BKRN-70000 Hemasterlins A & B, Fascaphysins (alkaloid), Alipkinidine (alkaloid), Isohomohalichondrin B, 5-methoxyamphimedine (alkaloid), Laulimalide/Fijianolide, Variolin (alkaloid).	Anticancer	41
<i>Xestospongia</i> sp	Renieramycin M (tetrahydroiso-quinoline) Genera - <i>Reniera</i>	Inhibit progression and metastasis of lung cancer cells.	80
<i>Monanchora pulchra</i>	Monanchocidin (polycyclic guanidine alkaloid)	Induced cell death in human monocytic leukemia (THP-1), human cervical cancer (HeLa) and mouse epidermal (JB6 Cl41) cells.	81
<i>Smenospongia</i> sp.	Smenospongine (sesquiterpene aminoquinone)	Induces antiangiogenic activities, antimicrobial, antiproliferative and cytotoxic.	82
<i>Spongia</i> sp.	Spongistatin-I (macrocyclic lactone polyether)	Mitosis inhibition, assembly of microtubule and the vinblastine binding to tubulin thereby inducing cytotoxic cell death in numerous cancer cell lines.	83

**Antifouling Effects:**

Natural sponge derived compounds were recently reviewed for antifouling effects with less toxic effect. Compounds derived from sponge exhibit settlement of barnacle larvae also inhibit fouling by macroalgae, or repel the blue mussel *Mytilus edulis galloprovincialis*. Antifouling property based compounds are highlighted in table 4.

**Table 4: Sponges exhibit antifouling property.**

Sponge	Compound	Reference
<i>Acanthella elongata</i>	Unknown	84
<i>Haliclona</i> sp. and <i>Reniera sarai</i>	poly 3-alkylpyridinium salts, saraine, and haminols	85
<i>Acanthella cavernosa/Halichondrida</i>	Kalihinene X (Isocyanoterpenoid)	86
<i>Acanthella cavernosa/Halichondrida</i>	Kalihipyan B (Isocyanoterpenoid)	87
<i>Acanthella cavernosa/Halichondrida</i>	10b-Formarnidokalihinol Isocyanoterpenoid	88
<i>Pseudoceratina purpurea/Verongida</i>	Pseudoceratidine 2, Dibromopyrrole-containing spermidine derivative	89
<i>Pseudoceratina purpurea/Verongida</i>	Ceratinamide A and B (Bromotyrosine derivative)	90
<i>Haliclona koremella/Haplosclerida</i>	C22 ceramide (Ceramide)	91
<i>Erylus formosus/Astrophorida</i> <i>Lendenfeldia chondrodes</i> <i>/Dictyoceratida</i>	Formoside Striterpene glycoside, sterol diperoxide	92
<i>Axinyssa</i> sp./ <i>Halichondrida</i>	Axinyssimides Sesquiterpene carbonimide Cdichlorides	93

### Anti -Malarial activity:

Certain compounds listed in the table 5 exhibit antimalarial activity. *Plasmodium* strains are mainly responsible for malaria. Multi-drug resistant plasmodium strains are emerging nowadays and it is very difficult to treat since those strains are resistant to many antibiotics chloroquine, pyrimethamine and sulfadoxine. To overcome this, new antimalarial drugs has to be emerged in order to fight against multidrug resistant plasmodium strains. Terpenoid isocyanates, isothiocyanates and isonitriles from sponges showed selective in vitro anti malarial activity against *Plasmodium falciparum*. Free carboxylic acids are used as precursors for synthesis of new cyclic norditerpene peroxides after esterification. These epidioxy-substituted norditerpenes and norsesterterpenes exhibit selective antimalarial activity against both chloroquine-sensitive and chloroquine-resistant *P. falciparum* strains.

**Table 5: Selective Sponges with anti malarial activity.**

Sponge	Compound	Target / Function	Reference
<i>Phakellia ventilabrum</i>	Alkaloids	<i>P. falciparum</i>	20
<i>Aplysinella strongylata</i>	Psammaphysin derivatives	Chloroquine-sensitive (3D7) <i>P. falciparum</i>	94
Petrosid Ng5 Sp5 (family Petrosiidae)	Pentacyclic alkaloids hydroxyingamine A and dihydroingenamine D], together with the known compound ingamine A	Strong antiplasmodial activity against chloroquine-sensitive (D6) and resistant (W2) strains of <i>Plasmodium falciparum</i> .	95
<i>Zyzya</i> sp.	Bispyrroloiminoquinone alkaloid, tsitsikammamine C	Inhibited both ring and trophozoite stages of the malaria parasite life cycle	96
<i>Zyzya</i> sp.	Makaluvamines and damirones A	Potent growth inhibitory activity against both <i>P. falciparum</i> lines	96
<i>Iotrochota</i> sp	N-cinnamoyl-amino acids, iotrochamides A and B	Inhibit <i>Trypanosoma brucei</i>	97
<i>Styliissa cf. massa</i>	8-isocyanato-15-formamidoamphilect-11(20)-ene and 8-iso thiocyanato-15-formamidoamphilect-11(20)-ene, (Diterpenes)	<i>P. falciparum</i>	98
<i>Verongula rigida</i>	Nine bromotyrosine-derived compounds	<i>Leishmania panamensis</i> , <i>Plasmodium falciparum</i> and <i>Trypanosoma cruzi</i> .	99
<i>Hymeniacidon</i> sp	Diterpenoid β-lactam alkaloid, Monamphilectine-A	<i>P. falciparum</i>	100
<i>Mycale laxissima</i> and <i>Clathria echinata</i>	Unknown	Exhibited promising antimalarial activities in the infection model of C57BL/6 mice with <i>Plasmodium berghei</i> ANKA	101
<i>Haliclona</i> sp./ <i>Haplosclerida</i> <i>Cymbastela hooperi</i> / <i>Halichondrida</i> <i>Diacarnus levii</i> / <i>Poecilosclerida</i>	Manzamine A (Alkaloids) diterpene isocyanates, isothiocyanates and isonitriles, norditerpenoid and norsesterterpenoid endoperoxides	<i>P. falciparum</i> , <i>T. gondii</i> , <i>P. berghei</i> ,	102
<i>Acanthella</i> sp./ <i>Halichondrida</i>	Kalihinol A Isonitril-containing	<i>P. falciparum</i>	103

	kalihinane diterpenoid		
<i>Cymbastela hooperi</i>	Diisocyanoadociane Tetracyclic diterpene	<i>P. falciparum</i>	104
	Halichondramide Macrolides	<i>P. falciparum</i>	105
<i>Diacarnus erythraeanus</i>	Sigmosceptrellin-B Norsesterpene acid	<i>T. gondii, P. falciparum</i>	105
<i>Agelas oroides</i>	(E)-Oroidin Alkaloids	<i>P. falciparum</i>	106
<i>Plakortis simplex</i>	Plakortin andDihydroplakortin Cycloperoxidase	<i>P. falciparum</i>	107
<i>Acanthella klethra/</i> <i>Halichondrida</i>	Axisonitrile-3 Sesquiterpenoid isocyanide	<i>P. falciparum</i>	108

### Larvicidal activity and Pesticidal Activity:

**Table 6: Marine sponges exhibiting larvicidal and Pesticidal activity.**

Sponge	Function	Reference
<i>Clathria gargonoids</i> and <i>callyspongia diffusa</i>	Larvicidal activity against culex and insecticidal properties.	20
<i>Sigmadosia carnosa</i>	Higher toxic effect on <i>Aedes egypti</i> .	20
<i>Haliclona pigmentifera,</i> <i>Petrosia similes</i>	Larvae of <i>A. janata</i> and <i>P. ricini</i>	20

### Compounds from Marine Sponges with diverse property:

**Table 11: Sponges with multiple applications.**

Sponge	Compound	Function	Reference
<i>Haliclona</i> sp.	Manzamine A, beta-carboline alkaloid	Anti-inflammatory activity, antifungal, anti-HIV-I activities with moderate antitumor activities	83
<i>Pachypellina</i> species	8-hydroxymanzamine A	Antitumor and anti HSV-II activity	41
<i>Axinyssa</i> sp. <i>Halichondria</i> sp. and <i>Chondrosia</i> <i>reticulata</i> .	Unknown	Anti-M tuberculosis activity	20
<i>Topsentia</i> sp.	Unknown	Strong hemolytic activity on fresh bovine erythrocytes.	20
<i>Myrmekioderma styx</i>	Unknown	Hemagglutination activity	20
<i>Spongia</i> sp. and <i>Spirastrella</i> sp.	spongistatins	Antiprolific activity	20
<i>Petrosia</i> sp.	Polyacetylenic alcohols, including (35,145)- petrocortyre A,	Cytotoxic activity against a small panel of human solid tumour cell liner by inhibiting DNA replication	109
<i>Ircinia ramosa</i>	Unknown	Possess antiviral, CNS stimulatory and antialgal properties	110
<i>Haliclona exigua</i>	Unknown	Antibacterial, Cytotoxic, Anti- inflammatory and Anti-oxidant activity	111

<i>Hippospongia</i> sp.	the pentacyclic sesterterpene, hippo spongeide A, and a scalarene sesterterpenoid, hippo spongeide B sesterterpenoids	Cytotoxic, Antispasmodic, and Antibacterial	112
<i>Jaspis stellifera</i>	stelletin (Isomalabaricane triterpenoids)	Cytotoxic	113
<i>Jaspis stellifera</i>	stelliferins A-F	Antineoplastic activity against both murine lymphoma (L1210) and human epidermoid carcinoma (KB) cells	114
<i>Stelletta globostellata</i>	isomalabaricane triterpenoids globostellatic acids	Cytotoxic activity against murine leukemia P388 cells	115
<i>Styliissa carteri</i>	Carteramine A	Anti-inflammatory (Neutrophil Chemotaxis inhibitor)	116
<i>Petrosia strongylata</i>	Acetylenic alcohols, petrosiols	Interfering PDGF-R $\beta$ signaling	117
<i>Rhaphisia lacazei</i>	Pyrazin-2(1H)-one	Interfering PDGF-R $\beta$ signaling	118
<i>Fasciospongia cavernosa</i>	Cacospongionolide B	Interfering NF- $\kappa$ B pathway	119
<i>Petrosaspongia nigra</i>	Petrosaspongiolide M	Interfering NF- $\kappa$ B pathway	119
<i>Hyrtios erectus</i>	Hyrtiosal	Interfering TGF- $\beta$ pathway	120
<i>Pandaros acanthifolium</i>	steroidal glycosides	Antioxidant and cytoprotective activities	121
<i>Agelas flabelliiformis</i> Carter (Agelasidae)	4a-merhyl-5a-cholest-8-en-3-ol 4,5-dibromo-2- pyrrolic acid	Immunosuppressive compounds	122
<i>Aurora globostellata</i>	Unknown	Immunomodulatory potential	123
<i>Cymbastela hooperi</i> ,	Diterpene isonitriles	Anti-fouling, anti-algal, anti-photosynthetic, anti-bacterial (Gram +ve and -ve), anti-fungal, and anti-tubercular activity	124
<i>Agelas linnaei</i> and <i>Ageles nakamurai</i>	alkaloid derivatives	Cytotoxic activity	125
<i>Amphimedon viridi</i> <i>Neopetrosia</i> sp.	Unknown	Antileishmanial activity	20

### Anti-inflammatory activity:

Acute inflammations in the human body arise as a result of microbial infection, physical damage, chemical agents and allergens. Blood flow changes results in increasing the permeability of the blood vessels thereby allows escape of cells from blood into tissues. Chronic inflammation of the skin or joints results in severe damage to if it leads to psoriasis or rheumatic arthritis. Sponges have been proved as an interesting source for anti-inflammatory compounds. Manolide is the first identified anti-inflammatory compound from Marine sponge with proven benefits. Mechanism of action is based on irreversible inhibition of the release of arachidonic acid from membrane phospholipids by preventing the enzyme phospholipase A2 from binding to the membranes. Few sponge derived compounds were found to inhibit lipoxygenase, another enzyme which is

involved in inflammation. Increase in the intracellular concentration of arachidonic acid results in the synthesis of inflammation mediators like leukotrienes and prostaglandins.

**Table 7: Species with anti inflammatory activity.**

Sponge	Compound/class	Target / Function	Reference
<i>Luffariella variabilis/</i> Dictyoceratida	Manoalide (Cyclohexane sesterterpenoid)	Phospholipase A2 inhibitor	126
<i>Dysidea</i> sp./ Dendroceratida	Dysidotronic acid (Drimane sesquiterpenoid)	Phospholipase A2 inhibitor	127
<i>Ircinia oros/</i> Dictyoceratida	Ircinin-1 and -2 (Acyclic sesterterpenoid)	Phospholipase A2 inhibitor	128
<i>Petrosaspongia nigra/</i> Dictyoceratida	Petrosaspongiolides M-R (Cheilantane sesterterpenoid)	Phospholipase A2 inhibitor	129
<i>Spongia</i> sp./ Dictyoceratida	Spongidines A-D (Pyridinium alkaloid)	Phospholipase A2 inhibitor	130
<i>Topsentia genitrix/</i> Halichondrida	Topsentin (Bis-indole alkaloid)	Phospholipase A2 inhibitor	131
<i>Cacospongia scalaris/</i> Dictyoceratida	Scalaradial (Scalarane sesterterpene)	Phospholipase A2 inhibitor	132
<i>Jaspis splendens/</i> Astrophorida	Jaspquinol (Diterpene benzenoid)	Lipoxygenase inhibitor	133
<i>Suberea</i> sp./Verongida	Subersic acid (Diterpene benzenoid)	Lipoxygenase inhibitor	133

#### Antiviral activity:

Several different sponges are rich source of bioactive compounds with antiviral properties. Screening and testing of anti-HIV agents from sponges led the researchers to gain interest to discover novel compounds. Eventhough lots of compound have been proved as anti-HIV agents the mechanism of action is still unclear. Despite of the introduction of HIV – inhibiting compounds from sponges, they do not have greater potential to fight against AIDS when compared with other viral diseases.

**Table 8: Compounds with antiviral properties.**

Sponge	Compound	Target / Function	Reference
<i>Jaspis</i> sp.	Jaspamide Macrocyclic depsipeptide	<i>C.albicans</i>	134
<i>Euryspongia</i> sp.	Eurysterols A-B (Sterols)	<i>C.albicans, Amphoterician B- resistant</i>	135
<i>Leucetta cf.</i> <i>chagosensis</i>	Naamine D (Imidazole alkaloid)	<i>C.neoformans</i>	136
<i>Monanchora</i> <i>unguifera</i>	Mirabilin B (Tricyclic guanidine Alkaloid)	<i>C.neoformans</i>	137
<i>Spongisorities</i> sp.	Hamacanthin A (Indole alkaloid)	<i>C.albicans</i>	138
<i>Spongisorities</i> sp.	Macanthins A-B (Indole alkaloid)	<i>C.albicans, C.neoformans</i>	138
<i>Agelas</i> sp.	Agelasines and Agelasimines Purine derivative	<i>C.krusei</i>	139
<i>Aaptos aaptos</i>	4-Methylaaptamine (Alkaloid)	Anti-viral (HSV-1)	140
<i>Theonella</i> sp.	Papuamides A-D (Cyclic depsipeptides)	Anti-viral (HIV-1)	141

<i>Cryptotethya crypta</i>	Vidarabine or Ara-A (Nucleoside)	HSV-1, HSV-2, VZV	142
<i>Dysidea avara</i>	Avarol Sesquiterpene hydroquinone	HIV-1, UAG suppressor Glutamine tRNA inhibitor	143
<i>Xestospongia</i> sp./ <i>Haplosclerida</i>	Haplosamates A and B (Sulfamated steroid)	Anti-viral (HIV-1 Integrase inhibitor)	144
<i>Halicortex</i> sp.	Dragmacidin F (Alkaloid)	HIV-1	145
<i>Hamigera tarangaensis</i>	Hamigeran B (Phenolic Macrolide)	Anti-viral (herpes and polio virus)	146
<i>Mycale</i> sp.	Mycalamide A-B (Nucleosides)	A59 coronavirus, (HSV-1)	147
<i>Siliquariaspongia mirabilis</i>	Mirabamides A, C and D (Peptide)	Antiviral (HIV-1)	148
<i>Styliissa carteri</i>	Oroidin (Alkaloid)	Antiviral (HIV-1)	149
<i>Sidonops microspinosa</i>	Microspinosamide (cyclic depsipeptide)	Anti-HIV activity	150
<i>Neamphius huxleyi</i>	Neamphamide	Inhibits HIV growth	150
Monanchora	Crambescidin	Inhibits HIV-1 envelope fusion with normal cells	151
Lendenfeldia (Madagascan sponge)	Dehydrofurodendin	Inhibits the RT-RNA and DNA directed DNA polymerases like polyacetylenetriol	152
<i>Petrosia similis</i>	Petrosins	Inhibits HIV growth	153
<i>Axinella cf. corrugata</i>	Esculetin ethyl ester	Inhibits the protease 3CL of the SARS enzyme & effective against Corona virus	154
Order- Verongida	Mololipids (Tyramine lipid)	Antiviral (HIV-1)	155
<i>Petrosia weinbergi/</i> <i>Haplosclerida</i>	Weinbersterols A and B (Sulfated sterol)	Antiviral (feline leukemia, mouse influenza, mouse corona)	156
<i>Kirkpatrickia varialosa/</i> <i>Poecilosclerida</i>	Variolin B (Pyridopyrrolopyrimidine alkaloid)	Antiviral	51
2', 5' Linked oligonucleotide	2-5A	Interferon mediator	157
<i>Polyfibrospongia</i> sp./ <i>Dictyoceratida</i>	Hennoxazole A Bisoxazole	Antiviral	158

### Neurosuppressives, Muscle Relaxants and Immunosuppressive Compounds:

Nitric oxide synthetase inhibitors downregulate Tcells and suppresses the immune system function thereby prevents the person from migraine attacks. Immune system suppression is the important process in case of hypersensitivity to certain allergens or other organ transplantations. In order to prevent rejection by the immune system, and also for several reasons compounds with medicinal value plays a significant role. Despite of several existing compounds, marine sponges are also considered as the source for development of immunosuppressive agents.

Neurosuppressive compounds interfere with neural communication which could be used as potent drug for neurologic disorders. Improper signaling in neuromuscular communication arises from stress which results in permanent muscle activation. Despite of these centrally acting muscle relaxants, which mediate neuromuscular communication, peripherally acting muscle relaxant can be used for local muscle relaxation. These can be applied for relief of strokes, or during intubations and surgery.

**Table 9: Compounds with immunosuppressive, neurosuppressive and muscle relaxant property.**

<b>Sponge</b>	<b>Compound</b>	<b>Function/Mode of action</b>	<b>Reference</b>
<i>Plakortis simplex/ Homosclerophorida</i>	Simplexides (Glycolipids)	Inhibitors of T cell Proliferation	159
<i>Dysidea sp./ Dendroceratida</i>	Polyoxygenated sterols (Sterol)	IL 8 inhibitor	160
<i>Petrosia contignata/ Haplosclerida</i>	Contignasterol (Oxygenated sterol)	Histamine release inhibitor	161
<i>Mycale sp./ Poecilosclerida</i>	Pateamine A (Thiazole macrolide)	IL-2 inhibitor	162
<i>Ianthella quadrangulata</i>	Iso-iantheran A (Polyketide)	Ionotropic P2Y11 receptor activation	163
<i>Dysidea herbacea/ Dendroceratida</i>	Dysiherbaine (Unusual amino acid)	Glutamate receptor antagonist	164
<i>Agelas sp. / Agelasida</i>	Keramadine (Pyrrole-guanidine Alkaloid)	Serotonergic receptor antagonist	165
<i>Tedania digitata / Poecilosclerida</i>	1-Methylisoguanosine (Nucleoside analogue)	Unknown (muscle relaxant, antiallergic)	166
<i>Xestospongia sp./ Haplosclerida</i>	Xestospongin C (Macrocyclic bis-oxaquinolizidine)	IP3-inhibitor	167
<i>Spongionella sp./ Dendroceratida</i>	Okinonellin B Furanosesterterpenoid	Unknown (muscle relaxant)	168
<i>Spongisorites sp./ Halichondrida</i>	Bromotopsentin (Bis-indole alkaloid)	$\alpha$ 1-Adrenergic receptor antagonist	169
<i>Penares sp./ Astrophorida</i>	Penaresidin A (Azetidine alkaloid)	Actomyosin ATPase inhibitor	170
<i>Dysidea sp./ Dendroceratida</i>	S1319 (Benzothiazole derivative)	Unknown (antiasthmatic, uterine relaxation)	171

**Cardiovascular agents:**

Sponge derived molecules has the ability to interfere with blood related diseases such as thrombosis, atherosclerosis or diabetes. Blood coagulation process is triggered by a complex proteolytic cascade which leads to the formation of fibrin. Thrombin, a serine protease cleaves a peptide fragment from fibrinogen, which then leads to the generation of fibrin, a major component of blood clots.

**Table 10: Selective compounds from Marine sponges as cardiovascular agents.**

<b>Sponge</b>	<b>Compound</b>	<b>Function</b>	<b>Reference</b>
<i>Theonella sp./ Lithistida</i>	Cyclotheonamide A Cyclic pentapeptide	Serine protease inhibitor and is a potential drug for the treatment of Thrombosis	172
<i>Eryltus formosus/ Astrophorida</i>	Eryloside F, Penasterol disaccharide	Thrombin receptor Antagonist	173
<i>Halichondria okadai/ Halichondrida</i>	Halichlorine, Cyclic aza-polyketide	VCAM-1 inhibitor	174
<i>Callyspongia truncata/ Haplosclerida</i>	Callyspongynic, Acid Polyacetylene	$\alpha$ -glucosidase inhibitor	175

**Analgesic Agents:**

Compound Ziconotide isolated from the marine snail *Conus magus*, recently approved by the FDA to treat pain. The mechanism of action of ziconotide is still unclear. Results in animal models suggest that ziconotide blocks the N-Type calcium channels on the primary nociceptive nerves in the spinal cord<sup>176</sup>.

### **Anti-oxidant activity:**

*Subergorgia suberosa* derived natural products exhibit anti oxidant activity. Bioactive diterpenes such as Subergorgic acid 1 presence in the marine sponge showed anti oxidant property<sup>177</sup>.

### **Conclusion:**

Marine sponges naturally produce enormous amount of bioactive compounds and secondary metabolites in association with other symbiotic species for its defense mechanisms. These bioactive compounds can be used as active metabolites to treat various infections as antimicrobial agents, antibiotic, anti-inflammatory compounds, immunosuppressive compounds and can also affect pathogenesis of many diseases. Compounds in nature target different substances in pathways or receptors and exhibits its inhibitory role. Inhibitory mechanism or its mode of action for certain compounds from marine sponges can be found out but for most of the substances their exact mode of action is not well known. In addition to that, limited tests make the substances to get their exact mode of action and their origin. Most of the bioactive substances exhibit their potential of inhibiting certain enzymes and it mediate or it acts as a mediator of certain intracellular or intercellular messengers directly involved in the pathogenesis of diseases. Moreover in the drug discovery process, substances which exhibited as potent inhibitors *in vitro* turned not to commercialize as drug after experimenting *in vivo*. It is mandatory that substances which are proved with inhibitory activity *in vitro* should produce better results in the *in vivo* condition. Those substances can be screened to commercialize as drug with better bioavailability with lesser side effects. Few compounds from marine sponges are existing as drugs in the market for various diseases. Potency of sponge derived medicines lies in the fact based on their efficacy, bioavailability and their side effects. In addition, the active core area of these molecules can be found and it can be used as a vehicle to derive many compounds as derivatives with their own specific efficacy and side effects. Most important challenging job in transforming bioactive molecules into medicine is to screen the treasure house of sponge metabolites and to select those displaying specific functions against a particular disease. But it should be decided that how these bioactive molecules can be produced in a large scale remains a question.

### **References:**

1. Bergquist P.R., Sponges, Hutchinson and Co. Ltd., London, UK, 268.
2. Faulkner D.J., Marine natural products, Nat Prod Rep., 2000, 17, 7-55.
3. Faulkner D.J., Marine natural products, Nat Prod Rep., 2001, 18, 1-49.
4. Thakur N.L, Hentschel U, Krasko A, Anil A.C. and W.E.G.Müller., Antibacterial activity of the sponge *Suberitesdomuncula* and its primmorphs: potential basis for chemical defense, Aquac Micro Ecol., 2003, 31, 77-83.
5. Amade P.H, Pesando D. and Chevolot L., Antimicrobial activities of marine from French Polynesia and Brittany, Mar. Biol., 1982, 70, 223-228.
6. Amade P, Charroin G, Baby C. and Vacelet J., Antimicrobial activity of marine sponges of Mediterranean Sea, Mar. Biol., 1987, 94, 271-275.
7. McCaffrey E.J. and Endeau R., Antimicrobial activity of tropical and subtropical sponges, Mar. Biol., 1985, 89, 1-8.
8. Uriz M.J, Martin D. and Rosell D., Relationships of biological and taxonomic characteristics to chemically mediated bioactivity in Mediterranean littoral sponges, Mar. Biol., 1992, 113, 287-297.
9. Xue S, Zhang H.T, Wu P.C, Zhang W. and Yuana Q., Study on bioactivity of extracts from marine sponges in Chinese Sea, J. Exp. Mar. Biol. Ecol., 2004, 298, 71-78.
10. Torres Y.R, Berlink R.G, Nascimento G.G, Fortier S.C, Pessoa C. and de Moraes M.O., Antibacterial activity against resistant bacteria and cytotoxicity of four alkaloid toxins isolated from the marine sponge, *Arenosclera brasiliensis*, Toxicon., 2002, 40, 885-891.
11. García-Ruiz J.C, Amutio E. and Pontón J., Invasive fungal infection in immunocompromised patients, Rev. Iberoam. Microl., 2004, 21, 55-62.

12. Pontón J, Rüchel R, Clemonds K.V, Coleman D.C, Grillot R, Guarro J, Aldebert D, Ambroise-Thomas P, Cano J, Carrillo- Muñoz A.J, Gené J, Pinel C, Stevens D.A. and Sullivan D., Emerging pathogens,Med. Mycol., 2000,38, 225-236.
13. Sandven P., Epidemiology of candidemia,Rev. Iberoam. Micol., 2000,17, 73-81.
14. Narlize Silva Lira, Ricardo Carneiro Montes, Josean Fechine Tavares, Marcelo Sobral da Silva EmidioV.L, da Cunha, Petronio Filgueiras de Athayde-Filho, Luis Cesar Rodrigues, Celidarque da Silva Dias, and Jose Maria Barbosa-Filho., Brominated Compounds from Marine Sponges of the Genus *Aplysina*and a Compilation of Their  $^{13}\text{C}$  NMR Spectral Data, Mar. Drugs., 2011, 9, 2316-2368.
15. Ulf Bickmeyera, Michael Assmann B, Matthias Kock B. and Christian Schutt., A secondary metabolite, 4,5-dibromopyrrole-2-carboxylic acid, from marine sponges of the genus *Agelas* alters cellular calcium signals, Environmental Toxicology and Pharmacology., 2005, 19, 423-427.
16. Davis R.A, Fechner G.A, Sykes M, Garavelas A, Pass D.M, Carroll A.R, Addepalli R, Avery V.M, Hooper J.N. and Quinn R.J., Dibromophakellin: an alpha $2\beta$  adrenoreceptor agonist isolated from the Australian marine sponge, *Acanthella costata*, Bioorg Med Chem., 2009, 6, 2497-500.
17. Fusetani N, MatsunagaS.and Konosu S., Bioactive marine metabolites II. Halistanol sulfate, an antimicrobial novel steroid sulfate from the marine sponge *Halichondria cf. moorei* bergquist, Tetrahedron letters.,1981,22, 1985-1988.
18. Richard M, Rosser and John Faulkner D., Two steroidal alkaloids from a marine sponge, *Plakina* sp, The Journal of Organic Chemistry., 1984, 49, 26.
19. Danielle Skropeta, Natalie Pastro and Ana Zivanovic., Kinase Inhibitors from Marine Sponges, Mar. Drugs., 2011, 9, 2131-2154.
20. Isaac Dhinakaran D. and Lipton A.P., Antimicrobial Potential of the Marine Sponge *Sigmadocia pumila*from the South Eastern Region of India, World Journal of Fish and Marine Sciences., 2012, 4, 344-348.
21. Moura R.M, Queiroz A.F.S, Fook J.M.S.L.L, Dias A.S.F, Monterio N.K.V, Ribeiro J.K.C,Moura G.E.D.D, Macedo L.L.P, Santos E.A. and Sales M.P., CvL a lectin from the marine sponge *Cliona varians*: isolation, characterization and its effects on pathogenic bacteria and *Leishmania promastigotes*. Comp. Biochem. Physiol., 2006, 145, 517-523.
22. Jirge Supriya S. and Chaudhari Yogesh S., Marine: The Ultimate Source of Bioactives and drug metabolites, IJRAP., 2010, 1, 55-62.
23. Rory Anthony Hutagalung, Victor, Myra Karjadidjaja, Vivitri Dewi Prasasty, and Noryawati Mulyono., Extraction and Characterization of Bioactive Compounds from Cultured and Natural Sponge, *Haliclona molita*and *Stylofella aurantium*Origin of Indonesia, Int J Biosci Biochem Bioinforma, 2014, 4, 1.
24. De Silva E.D. and Scheuer P.J., Three new sesterterpenoid antibiotics from the marine sponge *Luffariella variabilis* (Polejaeff), Tetrahedron Lett., 1981, 22, 3147-3150.
25. Matsunaga S, Fusetani N. and Konosu S., Bioactive marine metabolites, VII: structures of discodermins B, C, and D, antimicrobial peptides from the marine sponge *Discodermia kiiensis*, TetrahedronLett., 1985,26, 855-856.
26. Urban S, De Almeida Leone P, Carroll A. R, Fechner G. A, Smith J, Hooper J. N. and Quinn R.J., Axinellamines A-D, novel imidazo-azolo-imidazole alkaloids from the australian marine sponge *Axinellas*,J. Org. Chem., 1999,64, 731-735.
27. Linington R.G, Robertson M, Gauthier A, Finlay B.B, MacMillan J.B, Molinski T.F, van Soest R. and Andersen R.J.,Caminosides BD, Antimicrobial Glycolipids isolated from the Marine Sponge *Caminus sphaeroconia*,J. Nat. Prod., 2006,69, 173-177.
28. Rao V.K, Kasanah N, Wahyuono S, Tekwani B.L, Schinazi R.F. and Hamann M.T., Three new manzamine alkaloids from a common indonesian sponge and their activity against infectious and tropical parasitic diseases,J. Nat. Prod., 2004,67, 1314-1318.
29. Pettit R.K, Fakoury B.R, Knight J.C, Weber C.A, Pettit G.R, Cage G.D. and Pon S., Antibacterial activity of the marine sponge constituent cribrostatin 6,J. Med. Microbiol., 2004,53, 61-65.
30. Rubio B.K, van Soest R.W. and Crews P., Extending the record of meroditerpenes from *Cacospongia* marine sponges,J.Nat. Prod., 2007,70, 628-631.
31. Jang J.H, Van Soest R.W.M, Fusetani N, and Matsunaga S., Pseudoceratins A and B, antifungal bicyclic bromotyrosine-derived metabolites from the marine sponge *Pseudoceratina purpurea*,J. Org. Chem., 2007, 72, 1211-1217.

32. Gaspar H, Santos S, Carbone M, Rodrigues A.S, Rodrigues A.I, Uriz M.J, Savluchinske Feio S.M, Melck D, Humanes M. and Gavagnin M., Isomeric furanosesquiterpenes from the Portuguese marine sponge *Fasciospongia* sp, J. Nat. Prod., 2006, 71, 2049-2052.
33. Fusetani N, Yasumuro K, Matsunaga S. and Hashimoto K., Mycalolides A-C, hybrid macrolides of ulapualides and halichondramide, from a sponge of the genus *Mycale*, Tetrahedron Lett., 1989, 2809-2812.
34. Tsukamoto S, Matsunaga S, Fusetani N. and Van Soest R.W.M., Acanthosterol sulfates A-J: ten new antifungal steroid sulfates from a marine sponge *Acanthodendrilla* sp, J Nat Prod., 1998, 61, 1374-1378.
35. Nicolas G.M, Hong T.W, Molinski T.F, Lerch M.L, Cancilla M.T. and Lebrilla C.B Oceanapiside, an antifungal bis-a,x-amino alcohol glycoside from the marine sponge *Oceanapia philipensis*, J Nat Prod., 1994, 1678-1681.
36. D\_Ambrosio M, Guerriero A, Debitus C. and Pietra F., Leucascandrolide A, a new type of macrolide: the first powerfully bioactive metabolite of calcareous sponges (*Leucascandra caveolata*, a new genus from the coral sea), Helv Chim Acta., 1996, 79, 51-60.
37. Shen S, Liu D, Wei C, Proksch P. and Lin W., Purpuroines A-J, halogenated alkaloids from the sponge *Iotrochota purpurea* with antibiotic activity and regulation of tyrosine kinases, Bioorg Med Chem., 2012, 20, 6924-6928.
38. Lee Y, Jang K.H, Jeon J.E, Yang W.Y. and Sim C.J., Cyclic Bis-1,3- dialkylpyridiniums from the sponge *Haliclona* sp, Mar Drugs., 2012, 10, 2126-2137.
39. Huawei Zhang I.D, Menglian Dong, Jianwei Chen, Hong Wang, Karen Tenney and Phillip Crews., Bioactive Secondary Metabolites from the Marine Sponge Genus *Agelas*, Mar Drugs., 2017, 15, 351.
40. Rabelo L, Monteiro N, Serquiz R, Santos P. and Oliveira R., A lactose-binding lectin from the marine sponge *Cinachyrella apion* (Cal) induces cell death in human cervical adenocarcinoma cells, Mar Drugs., 2012, 10, 727-743.
41. Kamalakkannan P., Marine Sponges a Good Source of Bioactive Compounds in Anticancer Agents, Int. J. Pharm. Sci. Rev. Res., 2015, 31, 132-135.
42. Charan R.D, McKee T.C. and Boyd M.R., Thorectandrols A and B, new cytotoxic sesterterpenes from the marine sponge *Thorectandra* sp, J Nat Prod., 2001, 64, 661-3.
43. Fedoreev S.A, Prokof eva N.G, Denisenko V.A. and Rebachuk N.M., Cytotoxic activity of aaptamines from suberitid marine sponges, Pharm. Chem. J., 1988, 22, 615-618.
44. Kitagawa I, Kobayashi M, Kitanaka K, Kido M. and Kyogoku Y., Marine natural products, XII: on the chemical constituents of the Okinawan marine sponge *Hymeniacidon aldis*, Chem. Pharm. Bull., 1983, 31, 2321-2328.
45. Zapoliska-Downar D, Zapoliska-Downar A, Markiewski M, Ciechanowicz M, Kaczmarczyk, M. and Naruszewicz M., Selective inhibition by procubol of vascular cell adhesion molecule 1 (VCAM-1) expression in human vascular endothelial cells, Atherosclerosis., 2001, 155, 123-130.
46. Ter Haar E, Kowalski R.J, Hamel E, Lin C.M, Longley R.E, Gunasekera S.P, Rosenkranz H. S. and Day B.W., Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol, Biochem., 1996, 35, 243-250.
47. Hood K.A, West L.M, Rouwe B, Northcote P.T, Berridge M.V, Wakefield S.J. and Miller, J.H., Peloruside A, a novel antimitotic agent with paclitaxel-like microtubule-stabilizing activity, Cancer Res., 2002, 62, 3356-3360.
48. Juagdan E.G, Kalindindi R.S, Scheuer P.J. and Kelly-Borges M., Elenic acid, an inhibitor of topoisomerase II, from a sponge, *Plakinastrella* sp, Tetrahedron Lett., 1995, 36, 2905-2908.
49. Shimosaka A., Role of NKT cells and  $\alpha$ -galactosyl ceramide, Int. J. Hematol., 2002, 76, 277-279.
50. Jares-Erijman E.A, Sakai R. and Rinehart K.L., Crambescidins: new antiviral and cytotoxic compounds from the sponge *Crambe crambe*, J. Org. Chem., 1991, 56, 5712-5715.
51. Perry N.B, Ettouati L, Litaudon M, Blunt J.W and Munro M.H.G., Alkaloids from the antarctic sponge *Kirkpatrickia varialosa*, part 1: variolin B, a new antitumour and antiviral compound, Tetrahedron., 1994, 50, 3987-3992.
52. Pika J, Tischler M. and Andersen R.J., Glaciasterols A and B, 9,11-secosteroids from the marine sponge *Aplysilla glacialis*, Can J Chem., 1992, 70, 1506-1510.
53. Cheng S, Wen Z, Chiou S, Hsu C, Wang S, Dai C, Chiang M.Y. and Duh C., Durumolides A-E, anti-inflammatory and antibacterial cembranolides from the soft coral *Lobophytum durum*, Tetrahedron., 2008, 64, 9698-9704.

54. Kossuga M.H, Nascimento A.M, Reimão J.Q, Tempone A.G, Taniwaki N.N. and Veloso K., Antiparasitic, antineuroinflammatory and cytotoxic polyketides from the marine sponge *Plakortis angulospiculatus* collected in Brazil, *J Nat Prod.*, 2008, 71, 334–9.
55. Elhady S.S, El-Halawany A.M, Alahdal A.M, Hassanean H.A. and Ahmed S.A., A new bioactive metabolite isolated from the red sea marine sponge *Hyrtios erectus*, *Mol.*, 2016, 21, 82.
56. Willis R.H. and De Vries D.J., BRS1, a C30 bis-amino, bis-hydroxy polyunsaturated lipid from an Australian calcareous sponge that inhibits protein kinase C, *Toxicon.*, 1997, 35, 1125–1129.
57. Mooberry S.L, Tien G, Hernandez A.H, Plubrukarn A. and Davidson B.S., Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. *Cancer Res.*, 1999, 59, 653–660.
58. Anderson H.J, Coleman J.E, Andersen R.J. and Roberge M., Cytotoxic peptides hemiasterlin, hemiasterlin A and hemiasterlin B induce mitotic arrest and abnormal spindle formation, *Cancer Chemother Pharmacol.*, 1997, 39, 223–226.
59. Isbrucker R.A, Cummins J, Pomponi S.A, Longley R.E. and Wright A.E., Tubulin polymerizing activity of dictyostatin 1, a polyketide of marine sponge origin, *Biochem Pharmacol.*, 2003, 66, 75–82.
60. Hirata Y. and Uemura D., Halichondrins-antitumor polyether macrolides from a marine sponge, *Pure Appl Chem.*, 1986, 58, 701–710.
61. Bai R.L, Paull K.D, Herald C.L, Malspeis L, Pettit G.R. and Hamel E., Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin: discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data, *J Biol Chem* 266, 15882–15889.
62. Koiso Y, Morita K, Kobayashi M, Wang W, Ohyabu N. and Iwasaki S., Effects of arenastatin A and its synthetic analogs on microtubule assembly, *Chemico- Biol Interact.*, 1996, 102, 183–191.
63. Kashman Y, Graweiss A. and Shmueli U., Latrunculin, a new 2-thiazolidinone macrolide from the marine sponge *Latrunculia magnifica*, *Tetrahedron Lett.*, 1980, 21, 3629–3632.
64. Coue M, Brenner S.L, Spector I. and Korn E.D., Inhibition of actin polymerization by latrunculin A, *FEBS Lett.*, 1987, 213, 316–318.
65. Bubb M.R, Spector I, Bershadsky A.D. and Korn E.D., Swinholide A is a microfilament disrupting marine toxin that stabilizes actin dimers and severs actin filaments, *J Biol Chem.*, 1995, 270, 3463–3466.
66. Fusetani N, Takahashi M. and Matsunaga S., Topsentiasterol sulfates, antimicrobial sterol sulfates possessing novel side chains, from a marine sponge, *Topsentia* sp, *Tetrahedron.*, 1994, 50, 7765–7770.
67. Saito S, Watabe S, Ozaki H, Fusetani N. and Karaki H., Mycalolide, a novel actin depolymerizing agent, *J Biol Chem.*, 1994, 269, 29710–29714.
68. De Guzman F.S, Carte B, Troupe N, Faulkner D.J, Harper M.K, Conception G.P, Mangalindan G.C, Matsumoto S.S, Barrows L.R. and Ireland C.M., Neoamphimedine: a new pyridoacridine topoisomerase II inhibitor which catenates DNA, *J Org Chem.*, 64, 1400–1402.
69. Aoki S, Yoshioka Y, Miyamoto Y, Higuchi K, Setiawan A, Murakami N, Chen Z-S, Sumizawa T, Akiyama S.I. and Kobayashi M., Agosterol A, a novel polyhydroxylated sterol acetate reversing multidrug resistance from a marine sponge *Spongia* sp, *Tetrahedron Lett.*, 1998, 39, 6303–6306.
70. Erickson K.L, Beutler J.A, Cardellina J.H. and Boyd M.R., Salicylihalamides A and B, novel cytotoxic macrolides from the marine sponge *Haliclona* sp, *J Org Chem.*, 1997, 62, 8188–8192.
71. Cantrell C.L, Gustafson K.R, Cecere M.R, Pannell L.K. and Boyd M.R., Chondropsins A and B: novel tumor cell growth-inhibitory macrolide lactams from the marine sponge *Chondropsis* sp, *J Am Chem Soc.*, 2000, 122, 8825–8829.
72. Bowman E.J, Gustafson K.R, Bowman B.J. and Boyd M.R., Identification of a new chondropsin class of antitumor compound that selectively inhibits V-ATPases, *J Biol Chem.*, 2003, 278, 44147–44152.
73. Holland H.L, Kumaresan S, Tan L. and Njar V.C.O., Synthesis of 6-hydroximino-3-oxo steroids, a new class of aromatase inhibitor, *J Chem Soc Perkin Trans 1*, 585–587.
74. Rashid M.A, Gustafson K.R, Boswell J.L. and Boyd M.R., Haligramides A and B, two new cytotoxic hexapeptides from the marine sponge *Haliclona nigra*, *J Nat Prod.*, 2000, 63, 956–959.
75. Perry N.B, Blunt J.W, Munro M.H.G, Higa T. and Sakai R., Discorhabdin D an antitumor alkaloid from the sponges *Latrunculia brevis* and *Prianos* sp, *J Org Chem.*, 1998, 53, 4127–4128.
76. Kobayashi M, Higuchi K, Murakami N, Tajima H. and Aoki S., Callystatin A, a potent cytotoxic polyketide from the marine sponge, *Callyspongia truncata*, *Tetrahedron Lett.*, 1997, 38, 2859–2862.

77. Schmitz F.J, Gunasekera S.P, Yalamanchili G, Hossain M.B. and Van der Helm D., Tedanolide: a potent cytotoxic macrolide from the Caribbean sponge *Tedania ignis*, J Am Chem Soc 106., 1984, 7251–7252.
78. Randazzo A, Dal Piaz F, Orru S, Debitus C, Roussakis C, Pucci P. and Gomez-Paloma L., Axinellins A and B: new proline-containing antiproliferative cyclopeptides from the Vanuatu sponge *Axinella carteri*, Eur J Org Chem., 1998, 11, 2659–2665.
79. Casapullo A, Minale L. and Zollo F., New cytotoxic polyoxygenated steroids from the sponge *Dysidea incrassata*, Tetrahedron Lett., 1995, 36, 2669–2672.
80. Halim H, Chunhacha P, Suwanborirux K. and Chanvorachote P., Anticancer and antimetastatic activities of Renieramycin M, a marine tetrahydroisoquinoline alkaloid, in human non-small cell lung cancer cells, Antican Res., 2011, 31, 193-201.
81. Guzii A.G, Makarieva T.N, Denisenko V.A, Dmitrenok P.S. and Kuzmich A.S., Monanchocidin: a new apoptosis-inducing polycyclic guanidine alkaloid from the marine sponge *Monanchora pulchra*, Org Lett., 2010, 12, 4292-4295.
82. Kondracki M.L. and Guyot M., Smenosponge: a cytotoxic and antimicrobial aminoquinone isolated from *smedespongia*, Tetrah Lett., 1987, 27, 5815-5818.
83. Faircloth J.B., Capella L.M. and Alford B.L., The effect of brand attitude and brand image on brand equity, J Mark Theo and Prac., 2001, 9, 61–74.
84. Viswambaran Ganapiriy, Athisuyambulingam Maharanand Pothiappan Kumarasamy., Antifouling effect of bioactive compounds from marine sponge *Acanthella elongata* and different species of bacterial film on larval attachment of *Balanus amphitrite* (cirripedia, crustacea), Braz. Arch. Biol. Technol., 2012, 55, 395-402.
85. Elersek T, Kosi G, Turk T, Pohleven F. and Sepcic K., Influence of polymeric 3-alkylpyridinium salts from the marine sponge *Reniera sarai* on the growth of algae and wood decay fungi, Biofouling., 2008, 24, 137-43.
86. Okino T, Yoshimura E, Hirota H. and Fusetani N., Antifouling kalihinenes from the marine sponge *Acanthella cavernosa*, Tetrahedron Lett., 1995, 36, 8637– 8640.
87. Okino T, Yoshimura E, Hirota E. and Fusetani N., New antifouling kalihipyrans from the marine sponge *Acanthella cavernosa*, J Nat Prod., 1996, 59, 1081– 1083.
88. Hirota H, Tomono Y. and Fusetani N., Terpenoids with antifouling activity against barnacle larvae from the marine sponge *Acanthella cavernosa*, Tetrahedron., 1996, 52, 2359–2368.
89. Tsukamoto S, Kato H, Hirota H. and Fusetani N., Ceratinamides A and B: new antifouling dibromotyrosine derivatives from the marine sponge *Pseudoceratina purpurea*, Tetrahedron., 1996a, 52, 8181–4186.
90. Tsukamoto S, Kato H, Hirota H. and Fusetani N., Pseudoceratidine: a new antifouling spermidine derivative from the marine sponge *Pseudoceratina purpurea*, Tetrahedron Lett., 1996b, 37, 1439–1440.
91. Hattori T, Adachi K. and Shizuri Y., New ceramide from marine sponge *Haliclona koremella* and related compounds as antifouling substances against macroalgae, J Nat Prod., 1999, 61, 823–826.
92. Sera Y, Adachi K. and Shizuri Y., A new epidioxy sterol as an antifouling substance from a Palauan marine sponge, *Lendenfeldia chondrodes*, J Nat Prod., 1999, 62, 152–154.
93. Hirota H, Okino T, Yoshimura E. and Fusetani N., Five new antifouling sesquiterpenes from two marine sponges of the genus *Axinyssa* and the nudibranch *Phyllidia pustulosa*, Tetrahedron., 1998, 54, 1397–13980.
94. Mudianta I.W, Skinner-Adams T, Andrews K.T, Davis R.A. and Hadi T.A., Psammaphlysin derivatives from the Balinese marine sponge *Aplysinella strongylata*, J Nat Prod., 2012, 75, 2132-2143.
95. Ilias M, Ibrahim M.A, Khan S.I, Jacob M.R. and Tekwani B.L., Pentacyclic ingamine alkaloids, a new antiplasmodial pharmacophore from the marine sponge *Petrosid Ng5 Sp5*, Planta Med., 2012, 78, 1690-1697.
96. Davis R.A, Buchanan M.S, Duffy S, Avery V.M. and Charman S.A., Antimalarial activity of pyrroloiminoquinones from the Australian marine sponge *Zyzya* sp, J Med Chem., 2012, 55, 5851-5858.
97. Feng Y, Davis R.A, Sykes M.L, Avery V.M. and Quinn R.J., Iotrochamides A and B, antitrypanosomal compounds from the Australian marine sponge *Iotrochota* sp, Bioorg Med Chem Lett., 2012, 22, 4873-4876.
98. Chanthathamrongsiri N, Yuenyongsawad S, Wattanapiromsakul C. and Plubrukarn A., Bifunctionalized amphilectane diterpenes from the sponge *Styliissa cf. massa*, J Nat Prod., 2012, 75, 789-792.

99. Galeano E, Thomas O.P, Robledo S, Munoz D. and Martinez A., Antiparasitic bromotyrosine derivatives from the marine sponge *Verongula rigida*, Mar Drugs., 2011, 9, 1902-1913.
100. Avilés E. and Rodríguez A.D., Monamphilectine A, a potent antimalarial  $\beta$ -lactam from marine sponge *Hymeniacidon* sp: isolation, structure, semisynthesis, and bioactivity, Org Lett., 2010, 12, 5290-5293.
101. Mendiola Martínez J, Regalado Veloz C.E, Fernández-Calienes Valdés A, Acuña Rodríguez D. and Rojas Rivero C.L., In vivo antiplasmoidal activity of *Mycale laxissima* and *Clathria echinata* sponges, Rev Cubana Med Trop., 2012, 64, 244-255.
102. Ambrosio D, Guerriero M, Deharo A, Debitus E, Munoz C. and Pietra F., New types of potentially antimalarial agents: epidoxy- substituted norditerpene and norsesterpenes from the marine sponge *Diacarnuslevii*, Helv. Chim. Acta., 1998, 81, 1285-1292.
103. Ang K.K, Holmes M.J. and Kara U.A., Immune mediated parasite clearance in mice infected with *Plasmodium berghei* following treatment with manzamine A, Parasitol. Res., 2001, 87, 715-721.
104. Miyaoka H, Shimomura M, Kimura H, Yamada Y, Kim H.S. and Wataya Y., Antimalarial activity of kalahinol A and new relative diterpenoids from the Okinawan sponge, *Acanthella* sp. Tetrahedron., 1998, 54, 13467-13474.
105. Konig G.M, Wright A.D. and Angerhofer C.K., Novel potent antimalarial diterpene isocyanates, isothiocyanates, and isonitriles from the tropical marine sponge *Cymbastelahooperi*, J. Org. Chem., 1996, 61, 3259-3267.
106. Yousaf M.E, Sayed K.A, Rao K.V, Lim C.W, Hu J.F, Kelly M, Franzblau S.G, Zhang F, Peraud O, Hill R.T. and Hamann M.T., 12,34-Oxamanzamines, novel biocatalytic and natural products from manzamine producing Indo-Pacific sponges, Tetrahedron., 2002, 58, 7397-7402.
107. Tasdemir D, Topaloglu B, Perozzo R, Brun R, O'Neill R, Carballeira N.M, Zhang X, Tonge P. J, Linden A. and Rüedi P., Marine natural products from the Turkish sponge *Agelas oroides* that inhibit the enoyl reductases from *Plasmodium falciparum*, *Mycobacterium tuberculosis* and *Escherichia coli*, Bioorg. Med. Chem., 2007, 15, 6834-6845.
108. Angerhofer C.K, Pezzuto J.M, Konig G.M, Wright A.D. and Stichter O., Antimalarial activity of sesquiterpenes from the marine sponge *Acanthella klethra*, J Nat Prod., 1992, 55, 1787-1789.
109. De Rosa S, Tommonanaro G, Slantchev K, Stefanov K. and Popov., Lipophylic metabolites from the marine sponges *Ircinia muscarum* and its cell cultures, Mar Biol., 2002, 140, 465-470.
110. Thakur N.L. and Anil A.C., Antibacterial activity of the sponge *Ircinia ramosa*: Importance of its surface- associated bacteria, J Chemical Ecol., 2000, 26, 57-71.
111. Valentin Bhimba B, Cindhu Beulah M. and Vinod V., Efficacy of Bioactive Compounds extracted from marine sponge *Haliclona Exigua*, Asian J Pharm Clin Res., 2013, 347-349.
112. Kashman Y. and Rudi A., The  $^{13}\text{C}$  NMR spectrum and stereochemistry of heteronemin. Tetrahedron., 1977, 33, 2997-2998.
113. Ravi B.N, Wells R.J. and Croft K.D., Malabaricane triterpenes from a Fijian collection of the sponge *Jaspis stellifera*, J. Org. Chem., 1981, 46, 1998-2001.
114. Raeppe F, Weibel J.M. and Heissler D., Synthesis of the trans-syn-trans perhydrobenz[e]indene moiety of the stellettins and the stelliferins, Tetrahedron Lett., 1999, 40, 6377-6381.
115. Li J, Xu B, Cui J, Deng Z, de Voogd N.J, Proksch P. and Lin W., Globostelletins A-I, cytotoxic isomalabaricane derivatives from the marine sponge *Rhabdastrella globostellata*, Bioorg. Med. Chem., 2010, 18, 4639-4647.
116. Kobayashia H, Kitamurab K, Nagaic K, Nakaoa Y, Fusetania N. and Van Soestd R.W.M., Carteramine A, an inhibitor of neutrophil chemotaxis, from the marine sponge *Styliissa carteri*, Tetrahedron Lett., 2007; 48: 2127-9.
117. Choi B.K, Cha B.Y, Yagyu T, Woo J.T. and Ojika M., Sponge-derived acetylenic alcohols, petrosiols, inhibit proliferation and migration of platelet derived growth factor (PDGF)-induced vascular smooth muscle cells, Bioorg Med Chem., 2013, 21, 1804-10.
118. Pinchuk B, Johannes E, Gul S, Schlosser J, Schaechtele C. and Totzke F., Marine derived hamananthins as lead for the development of novel PDGFR beta protein kinase inhibitors, Mar Drugs., 2013, 11, 3209-23.
119. Posadas I, De Rosa S, Terencio M.C, Paya M. and Alcaraz M.J., Cacospongionolide B suppresses the expression of inflammatory enzymes and tumour necrosis factor-alpha by inhibiting nuclear factor-kappa B activation, Br J Pharmacol., 2003, 138, 1571-9.

120. Sun T, Wang Q, Yu Z, Zhang Y, Guo Y. and Chen K., Hyrtiosal, a PTP1B inhibitor from the marine sponge *Hyrtios erectus*, shows extensive cellular effects on PI3K/AKT activation, glucose transport and TGFbeta/Smad2 signaling, *Chembiochem.*, 2007, 8, 187–93.
121. Berrué F, McCulloch M.W, Boland P, Hart S. and Harper M.K., Isolation of steroidal glycosides from the Caribbean sponge *Pandaros acanthifolium*, *J Nat Prod.*, 2012, 75, 2094-2100.
122. Gunasekera S.P, Cranick S. and Longley R.E., Immunosuppressive compounds from a deep water marine sponge, *Agelas flabelliformis*, *J Nat Prod.*, 1989, 52, 757-761.
123. Chairman K, Jeyamala M, Sankar S, Murugan A. and Ranjit Singh., Immunomodulating properties of bioactive compounds present in *Aurora globostellata*, *Int J Mar Sci.*, 2013, 3, 151-157.
124. Wright A.D, Mccluskey A, Robertson M.J, MacGregor K.A. and Gordon C.P., Anti-malarial, anti-algal, anti-tubercular, anti-bacterial, anti-photosynthetic, and anti-fouling activity of diterpene and diterpene isonitriles from the tropical marine sponge *Cymbastela hooperi*, *Org Biomol Chem.*, 2011, 9, 400-407.
125. Blihoghe D, Manzo E, Villela A, Cutignano A. and Picariello G., Evaluation of the antifouling properties of 3-alkylpyridine compounds, *Biofouling.*, 2011, 27, 99-109.
126. Bennet C.F, Mong S, Clark M.A, Kruse L.J. and Crooke S.T., Differential effects of manoalide on secreted intracellular phospholipases. *Biochem Pharmacol.*, 1987, 36, 2079–2086.
127. Giannini C, Debitus C, Posadas I, Paya M. and DAuria M.V., Dysidotronic acid, a new and selective human phospholipase A2 inhibitor from the sponge *Dysidea* sp, *Tetrahedron Lett.*, 2000, 41, 3257–3260.
128. Cimino G, De Stefano S, Minale L. and Fattorusso E., Ircinin 1 and 2, linear sesterterpenes from the marine sponge *Ircinia oros*, *Tetrahedron.*, 1972, 28, 333–341.
129. Randazzo A, Debitus C, Minale L, Pastor P.G, Alcaraz M.J, Paya M. and Gomez-Paloma L., Petrosaspongiolides M-R: new potent and selective phospholipase A2 inhibitors from the New Caledonian marine sponge *Petrosaspongia nigra*, *J Nat Prod.*, 1998a, 61, 571–575.
130. De Marino S, Iorizzi M, Zollo F, Debitus C, Menou J.L, Ospina L.F, Alcaraz M.J. and Paya M., New pyridinium alkaloids from a marine sponge of the genus *Spongia* with a human phospholipase A2 inhibitor profile, *J Nat Prod.*, 2000, 63, 322–326.
131. Jacobs R.S, Koehn F.E. and Gunasekera S.P., Topsentin, a unique phospholipase A2 inhibitor [abstract]. Presented at the Japan–US Seminar on Bioorganic Marine Chemistry., 1994.
132. De Carvalho M.S. and Jacobs R.S., Two-step inactivation of bee venom phospholipase A2 by scalaradial, *Biochem Pharmacol.*, 1991, 42, 1621–1626.
133. Carroll J, Johnsson E.N, Ebel R, Hartman M.S, Holman T.R. and Crews P., Probing sponge-derived terpenoids for human 15-L-lipoxygenase inhibitors, *J Org Chem.*, 2001, 66, 6847–6851.
134. Zabriskie T.M, Klocke J.A, Ireland, C.M, Marcus A.H, Molinski T.F, Faulkner D.J, Xu C. and Clardy J.C., Jaspamide, a modified peptide from a *Jaspis* sponge, with insecticidal and antifungal activity, *J. Am. Chem. Soc.*, 1986, 108, 3123-3124.
135. Boonlarppradab C. and Faulkner D.J., Eurysterols A and B, cytotoxic and antifungal steroid sulfates from a marine sponge of the genus *Euryssporgia*, *J. Nat. Prod.*, 2007, 70, 846-848.
136. Dunbar D.C., Rimoldi J.M., Clark A.M., Kelly M. and Hamann M.T., Anti-cryptococcal and nitric oxide synthase inhibitory imidazole alkaloids from the calcareous sponge *Leucetta cf chagosensis*, *Tetrahedron.*, 2000, 56, 8795-8798.
137. Hua H.M, Peng J, Fronczeck F.R, Kelly M. and Hamann M.T. Crystallographic and NMR studies of antiinfective tricyclic guanidine alkaloids from the sponge *Monanchora unguifera*, *Bioorg. Med. Chem.*, 2004, 12, 6461-6464.
138. Oh K.B, Mar W, Kim S, Kim J.Y, Lee T.H, Kim J.G, Shin D, Sim C.J. and Shin J., Antimicrobial activity and cytotoxicity of bis (indole) alkaloids from the sponge *Spongisorites* sp, *Biol. Pharm. Bull.*, 2006, 29, 570-573.
139. Vik A, Hedner E, Charnock C, Tangen L.W, Samuelsen O, Larsson R, Bohlin L. and Gunderson L.L., Antimicrobial and cytotoxic activity of agelasine and agelasimine analogs, *Bioorg. Med. Chem.*, 2007, 15, 4016-4037.
140. Souza T.M, Abrantes J.L, de A Epifanio R, Leite Fontes C.F. and Frugulheti I.C., The alkaloid 4-methylnaptamine isolated from the sponge *Aaptos aaptosimpairs* Herpes simplex virus Type 1 penetration and immediate early protein synthesis, *Planta Med.*, 2007, 73, 200-205.
141. Ford P.W, Gustafson K.R, McKee T.C, Shigematsu N, Maurizi L.K, Pannell L.K., Williams D.E, De Silva E.D, Lassota P, Alien T.M, Van Soest R, Andersen R.J. and Boyd, M.R., Papuamides A-D, HIV-

- inhibitory and cytotoxic depsipeptides from the sponges *Theonella mirabilis* and *Theonella swinhonis* collected in Papua New Guinea, J. Am. Chem. Soc., 1999, 121, 5899-5909.
142. Faulkner D. J., Marine natural products, Nat. Prod. Rep., 2002, 19, 1-48.
143. Muller W.G, Sobel C, Diehl-Seifert B, Maidhof A. and Schroder H.C. Influence of the antileukemic and anti-human immunodeficiency virus agent avarol on selected immune responses *in vitro* and *in vivo*, Biochem. Pharmacol., 1987, 36, 1489-1494.
144. Qureshi A. and Faulkner D.J. Haplosamates A and B: new steroidal sulfamate esters from two haplosclerid sponges, Tetrahedron., 1999, 55, 8323-8330.
145. Cutignano A, Bifulco G, Bruno I, Casapullo A, Gomez-Paloma L. and Riccio R., Dragmacidin F: A New Antiviral Bromoindole Alkaloid from the Mediterranean Sponge *Halicortex sp.*, Tetrahedron., 2000, 56, 3743-3748.
146. Wellington K.D, Cambie R.C, Rutledge P.S. and Bergquist P.R., Chemistry of Sponges. 19 Novel Bioactive Metabolites from *Hamigeratarangaensis*, J. Nat. Prod., 2000, 63, 79-85.
147. Perry N.B, Blunt J.W, Munro M.H.G. and Thompson A.M., Antiviral and antitumor agents from a New Zealand sponge, *Mycale* sp. 2. Structures and solution conformations of mycalamides A and B, J. Org. Chem., 2000, 55, 223-227.
148. Plaza A, Gustchina E, Baker H.L, Kelly M. and Bewley C.A., Mirabamides A-D, depsipeptides from the sponge *Siliquariaspongia mirabilis* that inhibit HIV-1 fusion, J. Nat. Prod., 2000, 70, 1753-1760.
149. O'Rourke A, Kremb S, Bader T.M, Helfer M, Schmitt-Kopplin P, Gerwick W.H, Brack-Werner R. and Voolstra C.R., Alkaloids from the sponge *Styliissa carteri* present prospective scaffolds for the inhibition of human immunodeficiency Virus 1 (HIV-1), Mar. Drugs., 2016, 14, 28.
150. Oku N, Gustafson K.R, Cartner L.K, Wilson J.A, Shigematsu N. and Hess S., Neamphamide A, a new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge *Neamphius huxleyi*, J. Nat. Prod., 2004, 67, 1407-1411.
151. Chang L, Whittaker N.F. and Bewley C.A., Crambescidin 826 and dehydrocrambine A: new polycyclic guanidine alkaloids from the marine sponge *Monanchora* sp. that inhibit HIV-1 fusion, J. Nat. Prod., 2003, 66, 1490-1494.
152. Chill L, Rudi A, Aknin M, Loya S, Hizi A. and Kashman Y., New sesterterpenes from *Madagascan Lendenfeldia* sponges, Tetrahedron., 2004, 60, 10619-10626.
153. Venkateshwar Goud T, Srinivasa Reddy N, Raghavendra Swamy N, Siva Ram T. and Venkateswarlu Y., Anti-HIV active petrosins from the marine sponge *Petrosia similis*, Biol. Pharm. Bull., 2003, 26, 1498-1501.
154. De Lira S.P, Selegim M.H, Williams D.E, Marion F, Hamill P. and Jean F., A SARS-coronovirus <sup>3</sup>CL protease inhibitor isolated from the marine sponge *Axinella cf. corrugata*: structure elucidation and synthesis, J. Braz. Chem. Soc., 2007, 18, 440-443.
155. Ross S.A, Weete J.D, Schinazi R.F, Wirtz S.S, Tharnish P, Scheuer P.J. and Hamann M.T., Mololipids, a new series of anti-HIV bromotyramine-derived compounds from a sponge of the order Verongida, J. Nat. Prod., 2000, 63, 501-503.
156. Sun H.H, Cross S.S, Gunasekera M. and Koehn F.E., Weinbersteroldisulfates A and B, antiviral steroid sulfates from the sponge *Petrosia weinbergi*, Tetrahedron., 1991, 47, 1185-1190.
157. Kelve M, Kuusksalu A, Lopp A. and Reintamm T., Sponge (2,5)oligoadenylate synthetase activity in the whole sponge organism and in a primary cell culture, J Biotechnol., 2003, 100, 177-180.
158. Ichiba T, Yoshida W.Y, Scheuer P.J. and Higa T., Hennoxazoles, bioactive bisoxazoles from a marine sponge, J Am Chem Soc., 1991, 113, 3173-3174.
159. Costantino V, Fattorusso E, Mangoni A, Di Rosa M. and Ianaro A., Glycolipids from sponges, VII: simplexides, novel immunosuppressive glycolipids from the Caribbean sponge *Plakortis simplex*, Bioorg. Med. Chem. Lett., 1999, 9, 271-276.
160. de Almeida Leone, P, Redburn J, Hooper J.N. and Quinn R.J., Polyoxygenated dysidea sterols that inhibit the binding of [<sup>125</sup>I] IL-8 to the human recombinant IL-8 receptor type A, J. Nat. Prod., 2000, 63, 694-697.
161. Takei M, Burgoyne D.L. and Andersen R.J., Effect of contignasterol on histamine release induced by anti-immunoglobulin E from rat peritoneal mast cells, J. Pharm. Sci., 1994, 83, 1234-1235.
162. Northcote P.T, Blunt J.W. and Munro M.H.G., Pateamine: a potent cytotoxin from the New Zealand marine sponge, *mycale* sp., Tetrahedron Lett., 1991, 32, 6411-6414.

163. Greve H, Meis S, Kassack M.U, Kehraus S, Krick A, Wright A.D. and Konig G.M., New iantherans from the marine sponge *Ianthella quadrangulata*: novel agonists of the P2Y(11) receptor, *J. Med. Chem.*, 2007, 50, 5600–5607.
164. Sakai R, Kamiya H, Murata M. and Shimamoto K., A new neurotoxic amino acid from the Micronesian marine sponge *Dysidea herbacea*, *J Am Chem Soc.*, 1997, 119, 4112–116.
165. Nakamura H, Ohizumi Y. and Kaboyashi J., Keramadine, a novel antagonist of serotonergic receptors isolated from the Okinawan sea sponge *Agelas* sp, *Tetrahedron Lett.*, 1984, 25, 2475–2478.
166. Quinn R.J, Gregson R.P, Cook A.F. and Bartlett A.F., Isolation and synthesis of 1-methylisoguanisine, a potent pharmacologically active constituent from the marine sponge *Tedania digitata*, *Tetrahedron Lett.*, 1980, 21, 567–568.
167. De Smet P, Parys J.B, Callewaert G, Weidema A.F, Hill E, De Smedt H, Erneux C, Sorrentino V. and Missiaen L., Xestospongin C is an equally potent inhibitor of the inositol 1,4,5-triphosphate receptor and the endoplasmic-reticulum  $\text{Ca}^{2+}$  pumps, *Cell Calcium.*, 1999, 26, 9–13.
168. Kato Y, Fusetani N, Matsunaga S. and Hashimoto K., Okinonellins A and B, two novel furanoesterterpenes, which inhibit cell division of fertilized starfish eggs, from the marine sponge *Spongionella* sp, *Experientia.*, 1986, 42, 1299–1300.
169. Phife D.W, Ramos R.A, Feng M, King I, Gunasekera S.P, Wright A, Patel M, Pachter J.A. and Coval S.J., Marine sponge bis(indole) alkaloids that displace ligand binding to  $\alpha 1$ -adrenergic receptors, *Bioorg Med Chem Lett.*, 1996, 6, 2103–2106.
170. Kobayashi J, Cheng J.F, Ishibashi M, Walchli M.R, Yamamura S. and Ohizumi Y., Penaresidin A and B, two novel azetidine alkaloids with potent actomyosin ATPase activating activity from the Okinawan marine sponge *Penares* sp, *J Chem Soc Perkin Trans.*, 1991, 1, 1135–1138.
171. Suzuki H, Shindo K, Ueno A, Miura T, Takei M, Sakakibara M, Fukamachi H, Tanaka J. and Higa T., S1319: A novel  $\beta 2$ -adrenoceptor agonist from a marine sponge *Dysidea* sp, *Bioorg Med Chem Lett.*, 1999, 9, 1361–1364.
172. Maryanoff B.E, Qiu X, Padmanabhan K.P, Tulinsky A, Almond H.R, Andrade-Gordon P, Greco M.N, Kauffman J.A, Nicolaou Liu KC A, Brungs P.H. and Fusetani N., Molecular basis for the inhibition of human thrombin by the macrocyclic peptide cyclotheonamide A, *Proc Natl Acad Sci USA.*, 1993, 90, 8048–8052.
173. Stead P, Hiscox S, Robinson P.S, Pike N.B, Sidebottom P.J, Roberts A.D, Taylor N.L, Wright A.E, Pomponi S.A. and Langley D., Eryloside F, a novel penasterol disaccharide possessing potent thrombin receptor antagonist activity, *Bioorg Med Chem Lett.*, 2000, 10, 661–664.
174. Arimoto H, Hayakawa I, Kuramoto M. and Uemura D., Absolute stereochemistry of halichlorine; a potent inhibitor of VCAM-1 induction, *Tetrahedron Lett.*, 1998, 39, 861–862.
175. Nakao Y, Uehara T, Matsunaga S, Fusetani N, Van Soest R.W.M. and Matsunaga S., Callyspongynic acid, a polyacetylenic acid which inhibits  $\alpha$ -glucosidase, from the marine sponge *Callyspongia truncata*, *J Nat Prod.*, 2000, 65, 922–924.
176. Yogesh Murti. and Tarun Agrawal., Marine derived pharmaceuticalsDevelopment of natural health products from marine biodiversity, *International Journal of ChemTech Research.*, 2, 4, 2198-2217.
177. Rama Sekhara Reddy D, Amrutha.V.Audipudi, Damodar Reddy. G. and Bhaskar C.V.S., Antioxidant, Antiinflammatory and Antifungal Activity of Marine Sponge *Subergorgia suberosa*-Derived Natural Products, *International Journal of ChemTech Research.*, 3, 1, 342-348.

\*\*\*\*\*